OrigiMed is a Shanghai, China-based company focusing on the development of new oncology assays.
The latest round, led by Northpond Ventures, brings the total amount raised by the
company to date to $76 million.
The researchers developed a protocol for dengue and chikungunya virus detection, which they plan to continue to test for outbreak monitoring and diagnostics.
In an epigenome-wide association study of depression, the researchers tied DNA methylation to disease symptoms and suggested a role for axon guidance disruption.
To explore the genetic basis of clonal hematopoiesis and its consequences, researchers analyzed genotyping data for more than 151,000 UK Biobank participants.
The firm will use the proceeds to accelerate commercialization and deployment of its microfluidic technology and for working capital purposes.
Net proceeds from the exercise of subscription rights and warrants are anticipated to be $22.6 million, excluding any proceeds from the exercise of warrants.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.
Researchers characterized genetic, transcriptomic, and clinical features in advanced prostate cancers that emerged from treatment.
Researchers have found that the Btk-inhibitor ibrutinib, which is currently used to treat cancers that include types of lymphoma, could be effective in leukemia.
Using Cancer Genome Atlas data, the researchers identified about 1,100 genes in a range of cancer types whose expression is disrupted by structural variants.
Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.
Researchers from Belgium analyzed the transcriptomes of almost 100,000 single cells from lung cancer patients, most of them stromal cells.
An international team of researchers compared genetic changes that occur in the blood of people who develop acute myeloid leukemia and those who do not.
New genetic studies are providing insights into the molecular changes that occur as benign moles transition to melanoma and spread to other parts of the body by metastasis.
Analyst Puneet Souda said HTG has a growing funnel of biopharma projects that have the potential to convert to companion diagnostics with regulatory approval.
DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
The German Federal Joint Committee (G-BA) plans to decide on reimbursement of breast cancer biomarker tests in Q4.
The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.
A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.
The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."
In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.